The Latin American Stem Cell Market size is estimated to be growing at a CAGR of 10.9% during the forecast period. The market size is predicted to be worth USD 2327.83 million by 2026 from USD 1387.69 million in 2021.
Factors such as the growing geriatric population and incidences of chronic diseases such as cardiovascular, leukemia, cancer diseases, neurodegenerative disorders, and gastrointestinal diseases are majorly propelling the growth of the Latin American stem cell market. Strong support from government and private agencies is ascribed to boost up the demand of the market. A rising aging population and chronic diseases are key factors responsible for driving the stem cells market in this part of the world. In clinical research, to examine drug effectiveness, stem cells are used effectively, propelling the market's growth. The rise in the number of people suffering from chronic illnesses is an important factor for companies to expand the stem cell market in this region. The development of induced pluripotent stem cell lines also prompts demand for the stem cell market in this region.
However, the cost of stem cell therapies and research related to stem cells is restraining the demand for the market in this region.
This research report on the Latin American stem cell market has been segmented and sub-segmented into the following categories:
By Treatment mode:
By Cells Type:
By Technology:
By Country:
Geographically, the Mexican stem cell market is the most lucrative regional market in Latin America. An increase in the investment in research and development on stem cells is likely to bolster the market's demand. Developing countries like Argentina are esteemed to have a significant growth rate in the forecast period.
KEY MARKET PARTICIPANTS:
A few of the promising companies in the Latin American stem cell market profiled in this report are Athersys, StemCells Inc, Cryo-Cell International, Geron Corporation, Mesoblast Ltd, Aastrom Biosciences Inc, Celgene Corporation, Invitrogen and Cytori Therapeutics Inc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By mode of treatment
5.1.1 Autologous
5.1.2 Allogeneic
5.2 By application
5.2.1 CNS
5.2.2 CVS
5.2.3 GIT
5.2.4 Regenerative Medicine
5.2.5 Musculoskeletal
5.2.6 Eye & Immune System Development
5.2.7 Blood Disorders
5.3 By technology
5.3.1 Cell Acquisition
5.3.2 Cell Production
5.3.3 Cryopreservation
5.3.4 Expansion
5.3.5 Sub-Culture
5.4 By type
5.4.1 Adult Stem Cells
5.4.2 Human Embryonic Cells
5.4.3 Pluripotent Stem Cell
5.4.4 Natural Rosette Cells
6. Geographical Analysis
6.1 Introduction
6.2 Brazil
6.3 Mexico
6.4 Rest of Latin America
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Athersys
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 StemCells
8.3 Cryo Cell International
8.4 Geron Corporation
8.5 Mesoblast
8.6 Aastrom Biosciences
8.7 Celgene Corporation
8.8 Invitrogen
8.9 Cytori Therapeutics
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
